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Abstract 
Summary 
 
Objective    To evaluate blood lipid levels in the adult English population in 2006 and to 
report change in the use and efficacy of lipid-lowering treatment since 2003 after which time 
the general practicioner contract introduced a 'pay-per-performance' approach. 
 
Design    Cross Sectional surveys 
 
Participants    Nationally representative sample of 14142 non-institutionalised adults (>16 
years) living in England, partaking in the Health Survey for England 2006. 
 
Measurements    Mean levels of total, HDL, non-HDL and total: HDL cholesterol ratio, 
prevalence of hypercholesterolaemia, use of lipid lowering agents and lipid levels and control 
rates among those on treatment. 
 
Results    Age-standardised mean cholesterol levels fell from 5.49mmol/l in men and 
5.56mmol/l in women in 2003 to 5.26mmol/l and 5.37mmol/l respectively in 2006.  In 2006, 
59% of adults had a total cholesterol ≥5.0mmol/l and 11% reported lipid-lowering treatment, 
of whom 66% had a total cholesterol <5.0mmol/l and 22% were <4.0mmol/l.  The majority of 
those with established coronary heart disease, stroke or diabetes but fewer than one quarter 
of those with hypertension or ≥20% estimated 10 year cardiovascular risk and no 
established CVD took lipid-lowering drugs.  Lipid lowering treatment rates increased five-fold 
and control rates among the treated (to <5.0mmol/l) more than doubled between 1998 and 
2006.  About one third of those with established CVD or diabetes had cholesterol levels of 
<4.0mmol/l. 
 
Conclusions 
Previously reported improvements in treatment and control rates between 1998 and 2003 
continued between 2003 and 2006, with the biggest increases among those with established 
CVD and diabetes.  
 
247 words
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Introduction 
 Dyslipidaemia has long been established as a major risk factor for coronary 
heart disease (CHD).1  Since their successful introduction (some misplaced concerns 
notwithstanding)2, statins have shown clear benefits in the primary and secondary 
prevention of CHD and stroke in trials carried out in many regions of the world.3 
 Temporal patterns in CHD and stroke mortality vary around the world, 
depending on various factors including degree of development.  However in the UK, 
CHD mortality rates have fallen consistently since about 1980 partly reflecting falls in 
plasma cholesterol levels until the mid-1990s.4,5,6  Since then, improving lipid 
levels7,8 have accompanied beneficial lifestyle changes and increasing statin use.9 
 Over the last 17 years, with increasing evidence of the benefits of statins, the 
thresholds and targets for treating dyslipidaemia recommended in the UK have 
become increasingly aggressive.10-12  In 2004, the Quality and Outcomes Framework 
(QOF) introduced into the new General Medical Services Contract of General 
Practitioners in parts of the UK, included cholesterol treatment targets as part of this 
“pay-for-performance” system.13 
 Few nationally representative survey data are available to monitor blood lipid 
levels anywhere in the world.  However, the Health Survey for England (HSE), an 
annual health examination survey of the general population, intermittently focuses on 
cardiovascular disease and related risk factors and permits such evaluation of lipid 
levels.  We have used HSE 2006 data to describe mean lipid levels by age and sex 
in this nationally representative sample of the adult population in England; to 
examine whether there has been further improvement in treatment and control rates 
of dyslipidaemia; and the extent to which these changes are targeted towards those 
at highest cardiovascular risk.
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Methods 
Participants and data 
Data for this study come from the HSE in 2006, 20038 and 1998.7  The HSE is 
a series of large cross-sectional surveys of nationally representative samples of the 
free-living general population in England.  A new sample is selected each year.  
Details of the survey methods have been published elsewhere.7,8,14  Briefly, a 
random sample of postcode sectors was selected from the Postcode Address File, 
stratified by proportion of non-manual head of household, and a sample of 
addresses randomly selected from each postcode sector.  All adults (aged ≥16years) 
at each selected household were eligible.  Data were collected at two home visits: an 
interviewer administered a questionnaire on socio-demographic variables, lifestyle, 
general health, medication, and self-reported morbidity.  Secondly, a nurse asked 
further questions, including current prescribed medication and, for cardiovascular 
drugs, their purpose, and collected anthropometric and blood pressure 
measurements and a non-fasting blood sample.  Response rates and sample sizes 
for the three surveys are shown in Table 1. 
In 1998, 2003 and 2006, the survey included a module on cardiovascular 
disease.  In 2006, only a sub-sample of participants aged 65 and over were asked 
the CVD questions.  We classified participants as having CHD if they reported 
having doctor-diagnosed angina or heart attack.  Stroke and diabetes were also 
each defined as self-report of a doctor’s diagnosis.  The participant’s occupation was 
used to determine social class, categorised into manual or non-manual using the 
Registrar-General’s classification. 
 We defined hypertension as measured systolic blood pressure ≥140mmHg or 
diastolic ≥90mmHg (mean of the last two of three seated readings) or taking drugs 
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specifically for hypertension.15 Cardiovascular risk was estimated using the 
Framingham predictive equations.16 
The Biochemistry Department at the Royal Victoria Hospital, Newcastle 
analysed the  blood samples for total and HDL-cholesterol in all three years, using 
the same DAX Cholesterol Oxidase assay method on an Olympus 640 analyser 
calibrated to Centre for Disease Control guidelines.  A direct method (no 
precipitation) was used for HDL-cholesterol. 
Ethical approval was obtained prior to each survey from the Multi-centre 
Research Ethics Committees (MREC) in London.  Each participant gave verbal 
consent to be interviewed, visited by a nurse, and have blood pressure and 
anthropometric measurements taken, and written consent for blood sampling. 
 
Statistical Analyses 
Comparisons across time used directly age-standardised data, to the 
estimated sex-specific mid-year 2003 population of England.  Data from 2003 and 
2006 were weighted for non-response to make the sample representative of the 
general population; when analysing blood sample data, weights were further 
corrected for non-response to the blood samples to reduce bias and produce results 
that remained nationally representative.  Non-response weights have not been 
produced for the 1998 data because this was not government policy until 2003 due 
to good response rates in earlier surveys.  Data for 2003 and 2006 were analysed 
both with and without weighting and very similar results were obtained, so 
comparisons across the years are valid. 
   Mean total cholesterol and the proportion of participants exceeding various 
treatment thresholds overall and in different sub-groups were calculated.  For 2006, 
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analyses based on disease or risk status included only participants asked the CVD 
module; in these analyses (apart from Table 1), a separate weight was used that 
adjusted for the deficit in older participants to maintain the results as nationally 
representative.  Other analyses were based on all those with valid cholesterol 
measurements.  
All analyses were done in SPSSv15 and Stata v9.2, adjusting for the complex 
survey design. 
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Results 
 In 2006, 14,142 people aged ≥16 years were interviewed at home (61% of 
eligible adults), of whom 10,489 had a nurse visit.  Of these, 7,471 provided a blood 
sample from which lipid levels could be measured, 6,610 of whom had also been 
asked the CVD module (Table 1). 
 Those asked the CVD module and providing a blood sample in 2006 were 
predominantly non-manual (61%) and female (54%) with a mean age of 47.2 years.  
Only a small proportion of respondents were from ethnic minorities, or had self-
reported CHD, stroke or diabetes (Table 1).   
In 2006, total cholesterol was higher among women than men below age 25 and 
from age 55 onwards but HDL-cholesterol was higher among women at all ages 
(Figure 1a).  Total cholesterol rose among men until age 55 and fell thereafter 
whereas among women total cholesterol rose until age 65.  HDL-cholesterols were 
relatively stable in both sexes with increasing age with a tendency to be highest at 
age 45-64 in both sexes.  Non HDL-cholesterol (total minus HDL) was higher among 
men than women until age 55 (Figure 1a), whereas total:HDL-cholesterol ratios were 
higher among men at all ages (Figure 1b). 
 After the age of 44, women had a higher proportion of participants with mean 
total cholesterol levels at or above 6.5mmol/L and 5.0mmol/L - levels previously 
used as arbitrary cut points for normality10,11, but in all age groups a smaller 
proportion of women had total:HDL-cholesterol ratios ≥5 or ≥6 (Table 2). 
 In all age groups, except those aged ≥75, a greater proportion of men than 
women were on lipid-lowering treatment, rates being highest among men in the age 
range 65-74 and among women from age 75 onwards (Table 2).  Overall, 11% of 
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participants (12% of men and 10% of women) were on treatment; two-thirds of those 
on treatment (71% of men and 61% of women) had total cholesterol levels 
<5.0mmol/L and 22% (27% of men and 16% of women) <4.0mmol/L.  Rates of those 
reaching both targets were higher among men than women at all ages above 45. 
 Table 3 shows treatment and control rates (defined separately as total 
cholesterol <5.0mmol/L and <4.0mmol/l) among those aged 16-80 in whom 
treatment was indicated (i.e. total cholesterol ≥5.0mmol/l or on treatment), by 
disease or risk status.  High rates of treatment are apparent in those with either 
cardiovascular disease (CHD or stroke) or diabetes, but among hypertensive 
participants and those with high (≥20%) 10 year cardiovascular risk without 
established cardiovascular disease or diabetes <25% were treated.  Men were 
marginally more commonly treated than women except among those with high 
estimated cardiovascular disease risk.  Control rates to either target were more 
frequently reached among men than women except for those with self-reported 
hypertension and those at high estimated cardiovascular disease risk, using the 
5.0mmol/L target.  Over two-thirds of those on treatment with cardiovascular disease 
or diabetes were controlled to <5.0mmol/L but only about half of those with 
hypertension or high estimated cardiovascular disease risk were controlled.  About 
one in five women but two in five men with cardiovascular disease and on treatment 
reached the current target of <4.0mmol/L whereas about one-third of men and 
women with diabetes reached this target.  No important differences in lipid levels, 
treatment and control rates were apparent between socio-economic strata (non-
manual and manual) with or without diabetes or hypertension (data not shown). 
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Temporal Trends  
 The number of participants interviewed and studied in 2006 were 
smaller than in the two previous years (1998 and 2003) when cardiovascular disease 
was also the survey focus.  In 2006 among both men and women mean serum total 
cholesterol levels overall (5.26mmol/l and 5.37mmol/l respectively) were lower than 
in 2003 (5.49 and 5.56mmol/l) and 1998 (5.39 and 5.53mmol/l respectively, Table 4, 
as was the case among those with CHD, stroke, diabetes, hypertension or high 
10year cardiovascular disease risk.   
In all subgroups evaluated, the use of lipid-lowering drugs increased 
systematically across the three years, being highest among those with CHD.  
Overall, treatment rates increased four- to five-fold compared with 1998 (Table 4) 
and control rates (to <5.0mmol/L) among men on treatment rose from 31% in 1998 
to 65% in 2003 and to 71% in 2006 (Figure 2).  The equivalent figures for women 
were 20%, 45% and 61% respectively.  Similarly, patterns of treatment and control 
improved among men and women since 1998 and 2003 when earlier treatment 
thresholds of >6.5mmol/L were considered for comparison (Figure 2). 
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Discussion 
These extensive and most recent data from nationally representative samples 
of the English population show that in 2006 mean lipid levels were suboptimal for the 
majority of the population but significant improvements in total cholesterol levels are 
apparent compared with 2003 and 1998, overall and amongst various high-risk 
subgroups of the population.  The improved profiles among the untreated population 
presumably reflect some improving dietary and lifestyle factors.9  Reassuringly, 
although social class is often inversely related with health promotion advice on 
preventive care we found no sign of differential adverse lipid levels by socio-
economic status. 
Between 1998 and 2006, the use of lipid-lowering in the population overall 
has risen around five-fold, with dramatic increases in the absolute prevalence of the 
use of lipid-lowering agents among those with established cardiovascular disease or 
diabetes.  Nevertheless, even among those high risk groups, greater use of lipid-
lowering agents is warranted: among others for whom statin use is indicated18 
(hypertensive participants and those with a 10 year cardiovascular risk of ≥20% 
uncomplicated by established cardiovascular disease or diabetes12 ) fewer than one-
fifth were taking lipid-lowering therapy. 
Among those on lipid-lowering therapy, control rates (to total cholesterol 
<5.0mmol/L) rose significantly between 1998 and 20037 and again between 2003 
and 2006. 
It is not possible to evaluate exactly the extent to which the “pay-for-
performance” approach instigated in 2004 as part of the new General Medical 
Services Contract12 for general practitioners has contributed to the increasing 
treatment and control rates (points were awarded for effective lipid-lowering among 
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those with established cardiovascular disease or diabetes but not for other patients).  
However, the much lower absolute treatment rates among those for whom “pay-for-
performance” did not apply (e.g. those with a total: HDL-cholesterol ratio of ≥6,12 
hypertensives,18 and those with an estimated 10year cardiovascular disease risk 
≥20%) suggest that the GP contract has influenced prescribing practice.  The HSE 
database does not yet permit more detailed evaluation of the type and doses of lipid-
lowering agents used, but other data suggest that in 2006 over 90% of lipid-lowering 
prescriptions were for statins, of which simvastatin was the commonest agent used 
and the commonest prescribed dose was 40mg.19  Clearly, more effective lipid-
lowering could be achieved and thereby control rates improved by the use of more 
potent statins in some of those treated but not reaching current targets. 
In 2008 the latest NICE guidelines20 effectively recommend that for those with 
established cardiovascular disease, total and LDL cholesterol should be lowered with 
statins to <4.0mmol/L and <2.0mmol/L respectively.  Furthermore for those aged 30 
years and above with a 10year cardiovascular risk of ≥20%, simvastatin at 40mg 
should be prescribed irrespective of lipid levels.  If these two recommendations are 
adhered to, there is likely to be a dramatic increase in the overall use of and/or dose 
of statins because as of 2006 only 38% and 20% of treated men and women 
respectively with established cardiovascular disease had their total cholesterol 
controlled to <4.0mmol/L and fewer than one in five adults with 10year 
cardiovascular disease risk of ≥20% (up to one in five of the adult population in 
2006) were treated with lipid-lowering therapy. 
Limitations of these analyses include concerns associated with the relatively 
low response rate for the blood sample, which is lower than experienced in previous 
years but compatible with falling response rates around the world.21,22  To minimise 
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the potential bias derived from this low response, data were weighted for non-
response at each stage: to the interview using socio-demographic data and to the 
nurse visit and the blood samples using additional data available from all those 
interviewed.  The data presented are therefore reasonably representative of the non-
institutionalised adult population of England. 
Lipids were measured on only one occasion and hence data are susceptible to 
regression to the mean, thereby generating some misclassification among lipid level 
strata.  Furthermore, non-fasting blood samples were collected, which produces 
some inaccuracy in the measurement of HDL-cholesterol levels23 and precludes the 
evaluation of serum triglyceride levels.  Disease status was determined by self-
reported doctor-diagnosis and hence prone to some misclassification, while survey-
defined hypertension status may include a proportion of spurious cases because 
blood pressures were measured only at one visit in contradiction with currently 
recommended optimal practice.18  To compensate for this error, both survey-defined 
and self-reported hypertension data are presented in Table 3 to allow a comparison 
of the different potential sources of error.  Overall results between the two 
hypertension strata did not differ importantly.  The data may also be criticised for 
being over three years old but more contemporary nationally-representative data are 
not available.  Nevertheless it is likely that the changes apparent between 2003 and 
2006 will have increased in the years since 2006, although no new local guidelines 
relating to lipid-lowering were produced until the end of 2008.20  .Total cholesterol 
levels among the whole population were higher in 2003 than in 1998, both including 
and excluding those taking lipid-lowering drugs.  Small but significant beneficial 
changes were apparent from 2003 to 2006 among those not treated with lipid-
lowering therapy.  However, levels in 2006 were only marginally lower than in 1998 
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(though significantly so in women).  We are unable to explain the higher levels seen 
in 2003, which could be a chance finding, even with the sample sizes of these 
surveys. 
The main strength of this study is the use of consistent protocols for sampling, 
recruitment, obtaining information, and measuring cholesterol in all three studies.  
Falling CHD case fatality rates over the period of the surveys would tend to result in 
increased survival among those with higher mean cholesterol levels, suggesting that 
our findings represent real changes in cholesterol reduction and are not artefactual.  
This is one of the strengths of the use of repeated cross-sectional surveys on new 
individuals rather than a cohort study. 
Conclusions: 
In 2006, lipid levels among a large population-based representative sample of 
the English adult population were largely suboptimal but were better than in 1998 
and 2003.  These improvements reflect higher usage of lipid-lowering therapy, being 
11% of the population surveyed in 2006.  By 2006, lipid-lowering treatment rates had 
risen to about three-quarters of adults with established vascular disease and those 
with diabetes, but these rates should ideally rise to over 90%.  However, among 
those with a 10year cardiovascular risk of ≥20%, fewer than one in five adults were 
receiving lipid-lowering therapy.  Adequate control of total cholesterol (<5.0mmol/L) 
among those on lipid-lowering treatment was apparent among over three-quarters of 
men and over two- thirds of women with established cardiovascular disease or 
diabetes but only about half of treated hypertensives and those at ≥20% 10 year risk 
were controlled to this level. 
Nevertheless, the current trends in improving lipid profiles and increasing 
statin use are likely to continue in UK in light of recent more assertive guidance.20 
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Figure Legends 
Figure 1  Cholesterol levels by age and sex in 2006 
a Mean total, non-HDL, and HDL cholesterol 
b Total:HDL cholesterol ratio  
 
Figure 2  Changes over time in treatment and control † of different definitions of 
dyslipidaemia  
a Treatment threshold 6.5mmol/l Men  
b Treatment threshold 6.5mmol/l Women  
c Treatment threshold 5.0mmol/l Men  
d Treatment threshold 5.0mmol/l Women  
Footnote:. Data from 1998 unweighted; data from 2003 and 2006 weighted for blood 
sample non-response. 
† <5.0mmol/l  
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Table 1.  Adult participants (aged 16+) in the three surveys and characteristics 
of those with valid cholesterol measurements and asked the cardiovascular 
module questions 
 1998 2003* 2006* 
Household response rate 74% 73% 68% 
No. interviewed (response rate) 15,908 
(69%) 
14,836 
(66%) 
14,142 
(61%) 
No. with nurse visit (% of those with an 
interviewer visit) 
13,586 
(85%) 
11,408 
(77%) 
10,489 
(74%) 
No. agreeing to a blood sample (% of 
those with a nurse visit) 
10,773 
(79%) 
8,552 (75%)  8,181 
(78%) 
No. with Total- & HDL-cholesterol 
measurements 
10,538 8,274 6,610 † 
% male 47 46 46 
Mean age (SD) 48.2 (17.6)  49.5 (17.3)  47.2 (15.8)  
% non-manual 50 58 61 
% Asian ethnicity 2 3 5 
% Black ethnicity  1 1 2 
Prevalence of self-reported CHD (%) 6 5 4 
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 Prevalence of self-reported stroke (%) 2 2 1 
Prevalence of self-reported stroke but 
no CHD (%) 
1 2 1 
Prevalence of self-reported diabetes (%) 3 4 4 
Prevalence of self-reported diabetes (%) 
but no CHD or Stroke 
2 3 3 
Prevalence of self-reported 
hypertension (%) 
20 25 24 
Prevalence of self-reported 
hypertension but no CHD, Stroke or 
Diabetes (%) 
15 22 21 
Prevalence of survey-defined 
hypertension (%) 
37 33 28 
Prevalence of survey-defined  
hypertension but no CHD, stroke or 
diabetes (%) 
31 1630 24 
 % 10yr CVD risk ≥20% 27 22 15 
% 10yr CVD risk ≥20%, but no CHD, 
stroke or Diabetes 
24 21 13 
% taking lipid-lowering drugs 2 7 10 
 24 
Mean Total cholesterol (mmol/l) (SD) [all 
] 
5.53  (1.16)  5.64 (1.18) 5.43 (1.15) 
Mean Total cholesterol (mmol/l) (SD) 
[excluding those on lipid-lowering drugs] 
5.53  (1.16)  5.70 (1.18)  5.51 (1.13) 
Mean HDL cholesterol (mmol/l) (SD) 
[all] 
1.43 0.43) 1.52 (0.39) 1.49  (0.39) 
Mean HDL cholesterol (mmol/l) (SD) 
[excluding those on lipid-lowering drugs] 
1.43 (0.43) 1.53 (0.39) 1.50 (0.39) 
*Results in this table are unweighted and not age-standardised. 
† In HSE 2006, only a sub-sample of participants aged 65+ were asked the CVD 
module. Results in this table are restricted to those with cholesterol levels who were 
asked the CVD module. 
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Table 2. Prevalence and treatment of dyslipidaemia by different definitions and age, 2006 
 Age groups 
 16-44 45-64 65-74 75+ All (16+) 
 All Men Women All Men Women All Men Women All Men Women All Men Women 
% TC ≥ 
6.5mmol/l 
9 12 7 26 24 28 23 14 32 19 10 24 17 15 18 
% TC ≥ 
5.0mmol/l 
47 49 45 77 74 81 66 54 76 59 47 67 59 57 61 
% TC:HDL ≥ 
5 
14 22 6 19 26 11 14 18 11 10 14 8 15 22 8 
% TC:HDL ≥ 
6 
4 7 2 6 9 3 4 5 3 2 3 1 5 7 2 
% on 1 2 0 12 15 9 33 39 29 32 31 32 11 12 10 
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treatment 
% on 
treatment 
with TC 
<5.0mmol/l 
55 48 85 58 62 51 68 75 61 77 90 69 66 71 61 
% on 
treatment 
with TC 
<4.0mmol/l 
14 3 60 18 22 11 24 32 14 27 40 19 22 27 16 
Data have been weighted for non-response to blood sample. Results include people taking lipid-lowering drugs.
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 Table 3. Treatment and control rates by disease and cardiovascular disease risk status 2006 (age 16-80) 
 Disease or CVD risk category 
CHD or 
stroke* 
Diabetes* † Hypertension‡  ≥ 20% 10year 
CVD risk‡ 
Self-reported 
doctor-
diagnosed* 
Survey-defined§ 
Men Wome
n 
Men Wome
n 
Men Women Men Women Men Wome
n 
N 172 95 117 86 558 651 635 573 402 116 
% eligible for treatment 
(TC ≥ 5.0mmol/l or on 
treatment) 
87 98 78 86 79 84 81 88 87 95 
% of eligible being treated 87 72 79 76 25 19 19 18 17 19 
 28 
% on treatment with TC 
<5.0mmol/l 
84 70 81 67 52 53 54 50 49 50 
% on treatment with TC 
<4.0mmol/l 
38 20 34 33 12 10 13 9 2 0 
* Self-reported doctor-diagnosed disease 
† No CHD or stroke 
‡ No CHD, stroke or diabetes 
§ SBP ≥ 140mmHg or DBP ≥ 90mmHg  or taking drugs to reduce blood pressure 
Data have been weighted for non-response to blood sample, adjusted for the sub-sample included in the cardiovascular 
module. 
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Table 4.  Trends in mean cholesterol and use of lipid-lowering drugs in England, by disease group and sex, aged 
16+ 
 Men Women 
 1998 2003* 2006* 1998 2003* 2006* 
Mean cholesterol (mmol/l) (SE) 
With CHD†  5.54  (0.06) 4.79 (0.06) 4.45 (0.08) 6.23 (0.08) 5.47 (0.08) 5.06 (0.09) 
With stroke† ‡ 5.59 (0.14) 5.28 (0.16) 4.52 (0.21) 5.92 (0.13) 5.57 (0.15) 4.95 (0.13) 
With diabetes† § 5.45 (0.10) 5.07 (0.10) 4.55 (0.09) 5.95 (0.13) 5.48 (0.11) 4.78 (0.11) 
With hypertension† || 5.74 (0.04) 5.84 (0.04) 5.50 (0.04) 6.14 (0.04) 6.06 (0.04) 5.80 (0.04) 
With survey-defined hypertension|| # 5.69 (0.03) 5.91 (0.04) 5.61 (0.04) 6.17 (0.03) 6.24 (0.04) 5.92 (0.05) 
10yr CVD risk  ≥ 20%|| 5.96 (0.03) 6.09 (0.04) 5.71 (0.05) 6.62 (0.05) 6.70 (0.05) 6.28 (0.07) 
Low CVD risk (10yr risk ≤ 20%)|| 5.49  (0.02) 5.43 (0.02) 5.57 (0.03) 5.51 (0.02) 5.45 (0.02) 5.56 (0.02) 
All 5.39 (0.02) 5.49 (0.02) 5.26 (0.02) 5.53 (0.02) 5.56 (0.02) 5.37 (0.02) 
All, excluding those on lipid-lowering 
drugs 
5.40 (0.02) 5.57 (0.02) 5.36 (0.02) 5.53 (0.02) 5.63 (0.02) 5.44 (0.02) 
% on lipid-lowering drug(s)**       
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With CHD†  22 63 75 17 51 63 
With stroke† ‡ 6 33 47 11 26 58 
With diabetes† § 7 25 62 6 28 59 
With hypertension† || 2 9 19 3 7 16 
With survey-defined hypertension|| # 2 6 16 2 6 17 
10yr CVD risk ≥ 20%|| 2 5 15 2 5 17 
Low CVD risk (10yr risk ≤ 20%)|| 1 2 5 1 2 5 
All 2 7 12 2 5 9 
* Results for 2003 and 2006 are weighted for non-response to blood sample, adjusted for the sub-sample asked the 
cardiovascular module, and SE adjusted for complex survey design. Results are age-standardised to the 2003 mid-year 
population. Except where specified, results include people taking lipid-lowering drugs. 
† Self-reported doctor-diagnosed disease 
‡ No CHD 
§ No CHD or stroke 
|| No CHD, stroke or diabetes 
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# SBP ≥ 140mmHg or DBP ≥ 90mmHg  or taking drugs to reduce blood 
** Irrespective of total cholesterol level, so results for 2006 differ from those presented (for those aged 16-80) in Table 2  
